Singapore, Aug. 28 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator’s Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
Curie Oncology (Farrer)
National University Hospital
Trial Status: NA
Principal Investigator(s):
Dr John Chia Whay Kuang
Dr David Tan Shao Peng
Published by HT Digital Content Services with permission from Health Daily Digest....